What Pathologic Complete Response (pCR) Means

If you had chemotherapy, targeted therapy or immunotherapy before surgery — neoadjuvant treatment — then after the operation a pathologist examines everything that was removed: the breast tissue and the lymph nodes that were sampled. Pathologic complete response means no invasive cancer was found in any of it.

Not smaller. Not mostly gone. None detectable under the microscope in the tissue examined.

The FDA recognizes two definitions for regulatory purposes.

ypT0/is ypN0 — no residual invasive cancer in the resected breast specimen or the sampled nodes, with residual ductal carcinoma in situ permitted. This is the definition used most often.

ypT0 ypN0 — the stricter version, requiring the absence of both invasive and in situ disease.

Decoding the notation: 'y' signals that staging was performed after treatment rather than at diagnosis, and 'p' signals that it came from pathology rather than imaging. T refers to the tumor and N to the nodes.

The reason in situ disease is usually allowed is practical: outcome data track most closely with the elimination of invasive cancer, since in situ disease has not broken through into surrounding tissue and does not spread.

Neoadjuvant treatment produces something that adjuvant treatment cannot — a direct read on how your particular cancer responded to your particular drugs. Instead of estimating benefit from population averages, your team can see the result in the tissue.

Large pooled analyses of neoadjuvant trials have shown that people achieving pCR have better event-free and overall survival than those with residual disease. Crucially, that association is not uniform across breast cancer. It is strongest in triple-negative and HER2-positive disease — the subtypes that are most chemotherapy-sensitive and where pCR is most achievable — and considerably weaker in hormone receptor-positive, HER2-negative cancer, where much of the long-term benefit comes from years of endocrine therapy rather than from pre-surgical chemotherapy.

This is why the same result carries different weight depending on your subtype, and why your oncologist may frame it differently from something you have read.

It does not mean cure. Pathology can only report on the tissue that was removed. Microscopic cells elsewhere in the body are beyond its reach, and a minority of people who achieve pCR do still recur.

For that reason, treatment usually continues after surgery. Radiation may be recommended depending on the operation performed and the original stage. Endocrine therapy continues for hormone receptor-positive disease. HER2-directed treatment continues to complete the planned course. Achieving pCR generally does not mean stopping everything.

Most people do not, and residual disease is not a verdict on your treatment.

Substantial shrinkage without complete disappearance is a genuine response. And residual disease has become clinically actionable in its own right, precisely because it identifies people who benefit from more treatment after surgery. In HER2-positive breast cancer with residual invasive disease, the KATHERINE trial showed that switching to trastuzumab emtansine (T-DM1) after surgery improved outcomes compared with continuing trastuzumab. In triple-negative breast cancer with residual disease, the CREATE-X trial showed benefit from adjuvant capecitabine.

Pathologists also often report a residual cancer burden score, which grades how much disease remains from RCB-0 (equivalent to pCR) through RCB-III. This gives a more graded picture than a yes-or-no answer and can inform both prognosis and further treatment.

Complete pathologic response is assessed after neoadjuvant treatment in oesophageal, rectal, bladder and lung cancers among others, and is generally favourable wherever it is measured. In rectal cancer it has become central to watch-and-wait strategies for selected people. How strongly it predicts long-term outcome, and what follows from it, varies by cancer type.

The two things worth clarifying are which definition was applied, and what your result changes about the treatment ahead. Those two questions turn a piece of notation into information you can use.

• NCI Dictionary — pathologic complete response
• NCI Dictionary — neoadjuvant therapy
• NCI — Breast Cancer Treatment (PDQ), health professional version
• RECIST 1.1 response criteria